Currently Viewing:
Newsroom
Currently Reading
New Monoclonal Antibody Targeting MFAP5 Shows Activity Against Ovarian, Pancreatic Tumors, Study Says
July 22, 2019 – Alison Rodriguez
Personalized Cancer Vaccine Yields Promising Results for Patients With High-Risk Melanoma
July 18, 2019 – Jaime Rosenberg
Nivolumab, Ipilimumab Combo Demonstrates Clinical Benefit Among Adults With Pediatric Solid Tumors
July 15, 2019 – Jaime Rosenberg
UK Cancer Group Warns That Obesity Is Overtaking Smoking as Disease Driver
July 14, 2019 – Alison Rodriguez
Identifying Multiple Myeloma Treatment Patterns by Age and Region
July 12, 2019 – Laura Joszt
AJMC® in the Press, July 12, 2019
July 12, 2019 – AJMC Staff
CMS Proposes Bundled Payments for Radiation Oncology
July 11, 2019 – Jaime Rosenberg
Blinatumomab Reduces MRD Prior to HCT in Pediatric Patients With B-ALL
July 09, 2019 – Jaime Rosenberg
Authors Outline Steps to Better Imaging in Oncology
July 09, 2019 – Mary Caffrey

New Monoclonal Antibody Targeting MFAP5 Shows Activity Against Ovarian, Pancreatic Tumors, Study Says

Alison Rodriguez
Researchers from Houston Methodist Cancer Center and The University of Texas MD Anderson Cancer Center said they demonstrated a new monoclonal antibody blocked ovarian and pancreatic tumor activity in mice. 
For the majority of cases, ovarian and pancreatic cancers do not show early symptoms and therefore go undetected; however, researchers may have established a new immunologic approach to effectively fight these tumors, according to a study published in the Clinical Cancer Research journal.

The researchers developed a monoclonal antibody, which blocks the action of a protein—microfibril associated protein 5 (MFAP5)—secreted by the cells that surround the cancerous tumors. The Octet RED384 system determined the kinetics of binding affinity and the specificity of the antibody clones. Then, ovarian tumor and pancreatic tumor-bearing mouse models were used to test the efficacy of the immunotherapy.

"We found that blocking MFAP5 enhances the effectiveness of chemotherapy treatments and suppresses tumor growth in ovarian and pancreatic cancers, as well as inhibits progression of these two cancers in mice," Stephen T.C. Wong, PhD, from Houston Methodist Cancer Center and co-author of the study, said in a statement. "This new immunotherapy drug targets supporting cells surrounding a tumor rather than just the tumor cells alone. This tumor microenvironment contains newly developed blood vessels and fibrous connective tissue—created through the processes of angiogenesis and fibrosis —that feed and support the tumor."

Functional studies were conducted for 3 hybridoma clones which produced antibodies with high affinity and specificity to MFAP5. The anti-MFAP5 monoclonal antibody demonstrated an ability to down-regulate MFAP5-induced collagen production in cancer associated fibroblasts (CAFs), suppress intratumoral micro-vessel leakiness, and enhance paclitaxel bioavailability in both cancer models, according to the study. The results suggest that treatment strategies based on targeting CAF-derived MFAP5 activities are effective in suppressing cancer.

"MFAP5 promotes fibrosis in ovarian and pancreatic cancers, and fibrosis promotes progression, chemoresistance and reduces survival of people with these cancers,” noted Samuel Mok, PhD, from The University of Texas MD Anderson Cancer Center. “By blocking this secretory protein with an antibody, we can treat the tumor by targeting multiple cellular types—fibroblasts and blood vessels—in the tumor microenvironment."

Targeting MFAP5 demonstrates a new cancer treatment regimen and the researchers are working to designing a humanized anti-MFAP5 antibody for further development as a therapeutic agent for treating ovarian and pancreatic cancers. By the end of next year efficacy and toxicity testing will be completed, followed by a phase 1 clinical trial the following year, the researchers said. 

Reference

Yeung, Tsz-Lun, Leung, Cecilia S., et al. Anticancer immunotherapy by MFAP5 blockade inhibits fibrosis and enhances chemosensitivity in ovarian and pancreatic cancer [published

online July 22, 2019]. Clinical Cancer Research.

Related Articles

Improved Outcomes With Early Screening of Patients at Risk for Pancreatic Cancer
New Blood Biomarker Offers Earlier Detection of Pancreatic Cancer
Topline Results for Olaparib Maintenance Show Improved PFS in BRCA-Mutated Pancreatic Cancer
NCCN Ovarian Cancer Guidelines Add Options for PARP Inhibitors, Bevacizumab
Patients With Ovarian Cancer Could Benefit From More Genetic Testing
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up